Hailan Pharmaceutical (688302.SH) released its performance for the first three quarters, with a net loss of 0.154 billion yuan.

Zhitong Finance · Oct 25 19:49

Haisco Pharmaceutical (688302.SH) disclosed the third quarter report for 2024, achieving revenue in the first three quarters of the company 11...

According to the Zhixun Finance APP, Haisco Pharmaceutical (688302.SH) disclosed the third quarter report for 2024, achieving revenue of 0.11 million yuan in the first three quarters; net income attributable to the mother was a loss of 0.154 billion yuan; non-net income was a loss of 0.167 billion yuan; basic earnings per share was -1.56 yuan.

The translation is provided by third-party software.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.

海创药业(688302.SH)发布前三季度业绩，净亏损1.54亿元

Hailan Pharmaceutical (688302.SH) released its performance for the first three quarters, with a net loss of 0.154 billion yuan.

Risk Disclaimer

Statement